Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases

Table 6 Trials assessing the effect of VSL#3 in patients with cirrhosis

Ref.	Design	n	VSL#3 intake
Gupta et al[127], 2013	RCT	94 with cirrhosis	2 mo with 9 × 1011 CFU a day
Jayakumar et al[129], 2013	RCT	17 with decompensated cirrhosis; 15 completed	2 mo with 3.6 × 1012 bacteria a day
Rincón et al[128], 2014	Not mentioned	17 with cirrhosis and ascites; 12 completed	6 wk, the dose was not clear
Marlicz et al[130], 2016	Not mentioned	20 with cirrhosis (13 with compensated liver cirrhosis, 7 with decompensated liver cirrhosis), and 10 healthy controls	Daily for 28 d, the daily dose was not clear

RCT: Randomized controlled trial; CFU: Colony-forming unit.